Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
16-30 of 4470 results
VenatoRx secures $9.4m to develop new class of antibiotic fro multi-drug resistant bacteria
VenatoRx Pharmaceuticals, which focuses on discovery and development of novel therapies for highly drug resistant bacterial infections, has been awarded up to $9.4m from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator).
Drug Research > Drug Discovery & Development > News
VenatoRx Pharmaceuticals raises $42m in new funding round
VenatoRx Pharmaceuticals has raised $42m in a Series B funding round led by Versant Ventures and joined by Abingworth and Foresite Capital.
Drug Research > Drug Discovery & Development > News
Lilly and Nektar to jointly develop and commercialize autoimmune therapy
Eli Lilly and Company and Nektar Therapeutics have agreed to jointly develop NKTR-358, a novel immunological therapy discovered by the latter.
Drug Research > Drug Discovery & Development > News
Mitsubishi Tanabe to acquire NeuroDerm for $1.1bn
By PBR Staff Writer
Japan-based Mitsubishi Tanabe Pharma (MTPC) has agreed to acquire Israeli drug manufacturer NeuroDerm in an all-cash deal worth $1.1bn.
Drug Research > Drug Discovery & Development > News
UK awards more than £120m for global health research
The UK’s Department of Health has announced that 33 research units and groups will get over £120m funding for global health research.
Drug Research > Drug Discovery & Development > News
Mayo Clinic, nference launch startup company for drug development
By PBR Staff Writer
Mayo Clinic and nference have jointly formed a new startup to discover and develop therapies for diseases with unmet medical need using artificial intelligence (AI).
Drug Research > Drug Discovery & Development > News
Biognosys raises new funds to bring Proteomics to life science research market
Proteomics firm Biognosys has secured $5m funding from new and existing investors in an extended series C round.
Drug Research > Drug Discovery & Development > News
Celgene, BeiGene to advance PD-1 inhibitor for solid tumor cancers
By PBR Staff Writer
Celgene has agreed to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317 for the treatment of solid tumor cancers.
Drug Research > Drug Discovery & Development > News
GSK enters into drug discovery collaboration with Exscientia
By PBR Staff Writer
British drugmaker GlaxoSmithKline (GSK) has established a drug discovery collaboration with Frontier IP portfolio firm Exscientia.
Drug Research > Drug Discovery & Development > News
CytomX advances CD71-targeting probody drug conjugate into GLP toxicology studies
CytomX Therapeutics has advanced CX-2029, a probody drug conjugate (PDC) targeting CD71 and being developed in collaboration with AbbVie, into GLP toxicology studies, an important step on the path to filing an Investigational New Drug (IND) application next year.
Drug Research > Drug Discovery & Development > News
LifeArc, Dstl & CDRD partner to identify antibacterial drug targets
By PBR Staff Writer
UK-based LifeArc and Defence Science and Technology Laboratory (Dstl) will collaborate with Canada’s The Centre for Drug Research and Development (CDRD) to identify antibacterial drug targets.
Drug Research > Drug Discovery & Development > News
Arix Bioscience buys stake in Mitoconix Bio
Healthcare and life science firm Arix Bioscience has acquired a stake in Mitoconix Bio as part of an oversubscribed $20m Series A financing round.
Drug Research > Drug Discovery & Development > News
FDA accepts for filing Icon’s NDA for Dexycu drug therapy
The US Food and Drug Administration (FDA) has accepted for filing Icon Bioscience (IBI), recently submitted new drug application (NDA) for Dexycu (IBI-10090), a novel drug for treating inflammation associated with cataract surgery.
Drug Research > Drug Discovery & Development > News
Pfizer gets CRL on Epogen biosimilar from FDA
By PBR Staff Writer
The United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Pfizer in connection with its biosimilar candidate to Amgen’s anemia drug Epogen (epoetin alfa).
Drug Research > Drug Discovery & Development > News
Cancer frim Repare Therapeutics announces $68m Series A financing
Repare Therapeutics has secured $68m in a Series A financing round which it will use to advance its platform and pipeline of novel medicines that target genetically defined weaknesses of cancers.
Drug Research > Drug Discovery & Development > News
16-30 of 4470 results